Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

NCT01458054 | Completed Phase 1

• 1 other identifier: 115711
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a Phase I open label drug interaction study to evaluate the effect of omeprazole and ritonavir on GSK2336805.

Conditions

Hepatitis C

Keywords

pharmacokinetics; omeprazole; ritonavir; healthy subjects; drug interaction

Outcome Measures

Primary Outcomes (12)

• area under the plasma concentration time curve from time zero to the last quantifiable time points

  PK parameter

  48 hours

• under the plasma concentration time curve from time zero to infinity

  PK parameter

  48 hours

• area under the plasma concentration time curve from time zero to 24 hours

  PK parameter

  24 hours

• maximum observed concentration

  PK parameter

  48 hours

• time to maximum observed concentration

  PK parameter

  48 hours

• concentration at 24 hours post-dose

  PK parameter

  24 hours

• last measureable concentration

  PK parameter

  48 hours

• time of last measurable concentration

  PK parameter

  48 hours

• absorption lag time

  PK parameter

  48 hours

• the elimination half-life

  PK parameter

  48 hours

• apparent oral clearance

  PK parameter

  48 hours

• apparent volume of distribution

  PK parameter

  48 hours

Secondary Outcomes (5)

• Number of subjects with Adverse Events

  24 hours

• Number of subjects needing concurrent medications

  24 hours

• Number of subjects with clinical laboratory tests of clinical significance

  24 hours

• Number of subjects with electrocardiograms with clinically significant values

  24 hours

• Number of subjects with vital sign measures of clinical significance

  24 hours

Study Arms (7)

Treatment A

EXPERIMENTAL

GSK2336805 60mg x 1 dose (fasted) \[Reference Treatment\]

Drug: Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)

Treatment B

EXPERIMENTAL

Omeprazole 40 mg q24h x 4 days (fed)

Drug: Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)

Treatment C

EXPERIMENTAL

GSK2336805 60 mg x 1 dose and Omeprazole 40 mg on Day 1 (fasted) \[Test Treatment\]

Drug: Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)

Treatment D

EXPERIMENTAL

GSK2336805 30mg x 1 dose (fasted) \[Reference Treatment\]

Drug: Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)

Treatment E

EXPERIMENTAL

Ritonavir 100mg q12h x 4 days (fed)

Drug: Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)

Treatment F

EXPERIMENTAL

GSK2336805 30 mg x 1 dose (fasted) and ritonavir 100mg q12h on Day 1 (fasted) \[Test Treatment\]

Drug: Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)

Treatment G

EXPERIMENTAL

Ritonavir 100mg q12h x 1 day

Drug: Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)

Interventions

Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose) DRUG

GSK2336805 and Omeprazole

Treatment A; Treatment B; Treatment C

Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose) DRUG

GSK2336805 and Ritonavir

Treatment D; Treatment E; Treatment F; Treatment G

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin greater than or equal to 1.5x Upper Limit of Normal (ULN) (isolated bilirubin greater than 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin less than35%).
• Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. Subjects with values outside the normal range should always be excluded from enrollment.
• Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.
• A female subject is eligible to participate if she is of:
• Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, oophorectomy, or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea
• Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until the follow up visit.
• Body weight greater than or equal to 50 kilograms for men and greater than or equal to 45 kilograms for women. Body mass index (BMI) between 18.5-32 inclusive will be allowed (inclusive).
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
• QTcB less than 450; or QTc less than 480 in subjects with Bundle Branch Block

You may not qualify if:

• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
• Where participation in the study would result in donation of blood or blood products in excess of 500 milliliters within a 56 day period.
• Pregnant females as determined by positive serum or urine human chorionic gonadotropin test at screening or prior to dosing.
• Lactating females.
• Unwillingness or inability to follow the procedures outlined in the protocol.
• Subject is mentally or legally incapacitated.
• History of sensitivity to heparin or heparin-induced thrombocytopenia.
• History or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
• Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
• The subject's systolic blood pressure is outside the range of 90-140, or diastolic blood pressure is outside the range of 45-90 or heart rate is outside the range of 50-100 beats per minute (bpm) for female subjects or 45-100 beats per minute for male subjects.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Buffalo, New York, 14202, United States

Location

Related Links

• Results for study 115711 can be found on the GSK Clinical Study Register.

MeSH Terms

Conditions

Hepatitis C

Interventions

GSK2336805; Omeprazole; Ritonavir

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Hepatitis, Viral, Human; Virus Diseases; Flaviviridae Infections; RNA Virus Infections; Hepatitis; Liver Diseases; Digestive System Diseases

Intervention Hierarchy (Ancestors)

2-Pyridinylmethylsulfinylbenzimidazoles; Sulfoxides; Sulfur Compounds; Organic Chemicals; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Benzimidazoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Thiazoles; Azoles

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 6, 2011
• First Posted: October 24, 2011
• Study Start: September 27, 2011
• Primary Completion: November 28, 2011
• Study Completion: November 28, 2011
• Last Updated: July 21, 2017

Record last verified: 2017-07

Locations

US (1)